MedNews Week | Oncology Unplugged With Dr Chandler Park

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Chandler Park, MD, MSc, FACP

November 6th 2024

Chandler Park, MD, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Chandler Park, MD, MSc, FACP;Stephanie L. Graff, MD, FACP

September 4th 2024

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Chandler Park, MD, MSc, FACP;Pashtoon M. Kasi, MD, MS

August 21st 2024

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Chandler Park, MD, MSc, FACP;Petros Grivas MD, PhD

August 7th 2024

Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Chandler Park, MD, MSc, FACP;Guru Sonpavde, MD

July 24th 2024

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.

Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer

Chandler Park, MD, MSc, FACP;Guru Sonpavde, MD

July 10th 2024

Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Chandler Park, MD, MSc, FACP;Guru Sonpavde, MD

May 30th 2024

Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial of enfortumab vedotin plus pembrolizumab in urothelial carcinoma.